Tenax Therapeutics Inc
TENX6.110USD
-0.110-1.77%
Market hours （ET）Quotes delayed by 15 min
24.26MMarket Cap
LossP/E TTM
More Details of Tenax Therapeutics Inc Company
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 (IV), TNX-102 (subcutaneous) and TNX-103 (oral) levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Company Info
Ticker SymbolTENX
Company nameTenax Therapeutics Inc
IPO dateOct 28, 1993
CEOMr. Christopher T. (Chris) Giordano
Number of employees4
Security typeOrdinary Share
Fiscal year-endOct 28
Address101 Glen Lennox Drive
CityCHAPEL HILL
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code27517
Phone19198552100
Websitehttp://www.tenaxthera.com/
Ticker SymbolTENX
IPO dateOct 28, 1993
CEOMr. Christopher T. (Chris) Giordano
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Stuart Rich, M.D.
Dr. Stuart Rich, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
2.65K
--
Dr. Declan Doogan, M.D.
Dr. Declan Doogan, M.D.
Independent Director
Independent Director
2.27K
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Independent Chairman of the Board
Independent Chairman of the Board
1.67K
--
Mr. Thomas A. (Tom) Mcgauley
Mr. Thomas A. (Tom) Mcgauley
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. June Almenoff, M.D., Ph.D.
Dr. June Almenoff, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Christopher T. (Chris) Giordano
Mr. Christopher T. (Chris) Giordano
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Robyn M. Hunter
Ms. Robyn M. Hunter
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Stuart Rich, M.D.
Dr. Stuart Rich, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
2.65K
--
Dr. Declan Doogan, M.D.
Dr. Declan Doogan, M.D.
Independent Director
Independent Director
2.27K
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Independent Chairman of the Board
Independent Chairman of the Board
1.67K
--
Mr. Thomas A. (Tom) Mcgauley
Mr. Thomas A. (Tom) Mcgauley
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. June Almenoff, M.D., Ph.D.
Dr. June Almenoff, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Christopher T. (Chris) Giordano
Mr. Christopher T. (Chris) Giordano
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RTW Investments L.P.
9.12%
The Lind Partners, LLC
9.04%
Dellora Investments LP
8.46%
BVF Partners L.P.
8.18%
Millennium Management LLC
5.63%
Other
59.56%
Shareholders
Shareholders
Proportion
RTW Investments L.P.
9.12%
The Lind Partners, LLC
9.04%
Dellora Investments LP
8.46%
BVF Partners L.P.
8.18%
Millennium Management LLC
5.63%
Other
59.56%
Shareholder Types
Shareholders
Proportion
Hedge Fund
30.53%
Investment Advisor/Hedge Fund
18.96%
Venture Capital
10.04%
Investment Advisor
9.19%
Research Firm
2.85%
Individual Investor
0.23%
Other
28.19%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
58
2.98M
71.81%
+994.85K
2025Q1
58
2.74M
66.20%
+755.49K
2024Q4
56
1.98M
58.13%
+213.72K
2024Q3
58
1.98M
66.48%
+633.55K
2024Q2
48
161.28K
18.23%
+129.16K
2024Q1
48
149.68K
17.63%
+121.80K
2023Q4
43
26.36K
16.08%
+6.23K
2023Q3
45
17.13K
13.16%
+882.00
2023Q2
48
14.32K
12.38%
-2.77K
2023Q1
49
16.81K
20.77%
+6.69K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RTW Investments L.P.
378.35K
9.12%
+378.35K
--
Mar 31, 2025
The Lind Partners, LLC
375.00K
9.04%
+305.00K
+435.71%
Sep 30, 2024
Dellora Investments LP
351.07K
8.46%
--
--
Mar 05, 2025
BVF Partners L.P.
339.55K
8.18%
--
--
Mar 31, 2025
Millennium Management LLC
233.62K
5.63%
+206.99K
+777.40%
Jun 26, 2025
VR Adviser, LLC
208.33K
5.02%
--
--
Mar 31, 2025
Vivo Capital, LLC
208.33K
5.02%
--
--
Mar 31, 2025
Integral Health Asset Management, LLC
167.00K
4.03%
+167.00K
--
Mar 31, 2025
Janus Henderson Investors
166.67K
4.02%
--
--
Mar 31, 2025
Morgan Stanley & Co. LLC
117.83K
2.84%
+45.66K
+63.27%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
DFA Dimensional US Sustainability Core 1 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 29, 2023
Merger
80<1
Dec 29, 2023
Merger
80<1
Dec 29, 2023
Merger
80<1
Dec 29, 2023
Merger
80<1
Jan 04, 2023
Merger
20<1
Jan 04, 2023
Merger
20<1
Date
Type
Ratio
Dec 29, 2023
Merger
80<1
Dec 29, 2023
Merger
80<1
Dec 29, 2023
Merger
80<1
Dec 29, 2023
Merger
80<1
Jan 04, 2023
Merger
20<1
Jan 04, 2023
Merger
20<1
Jan 04, 2023
Merger
20<1
Jan 04, 2023
Merger
20<1
